[The acquisition is expected to close on or around November 1, 2012]
Online PR News – 18-October-2012 – Las Vegas, NV – CytRx Corporation (NASDAQ: CYTR) CYTR recently reported that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma was presented at the Sarcoma Poster-Discussion Session (Hall H) at the ESMO (European Society of Medical Oncology) 2012 Congress in Vienna, Austria. The presentation, entitled INNO-206 (aldoxorubicin) Is An Active Drug For Relapsed Soft Tissue Sarcoma, was given by renowned sarcoma expert Sant P. Chawla, M.D., Director of the Sarcoma Oncology Center in Santa Monica, CA. The data from the aldoxorubicin Phase 1b/2 clinical trial showed clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with aldoxorubicin at the maximum tolerated dose in 10 of 13 (77%) evaluable patients with relapsed or refractory soft tissue sarcoma. CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, recently initiated both a Phase 2 trial for patients with advanced pancreatic ductal adenocarcinomas and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and plans to meet with the FDA in the fourth quarter of 2012 to discuss a potential Phase 3 pivotal trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com.
Titan Machinery Inc. (NASDAQ: TITN) TITN reported that it has entered into an agreement to acquire Toners Inc., which consists of three CaseIH agricultural equipment dealerships located in Grand Island (currently Toners, Inc.), Broken Bow (currently Red Line Equipment) and Ord (currently Ord Equipment), Nebraska. The acquisition is expected to close on or around November 1, 2012. Titan Machinery Inc. (NASDAQ: TITN), founded in 1980 and headquartered in West Fargo, North Dakota, is a multi-unit business with mature locations and newly-acquired locations. The Company owns and operates a network of full service agricultural and construction equipment stores in the United States and Europe. Upon the closing of the Toners Inc. acquisition, the Titan Machinery network will consist of 102 North American dealerships in North Dakota, South Dakota, Iowa, Minnesota, Montana, Nebraska, Wyoming, Wisconsin, and Colorado, including two outlet stores, as well as 12 European dealerships in Romania and Bulgaria. The Titan Machinery dealerships represent one or more of the CNH Brands (NYSE: CNH), a majority-owned subsidiary of Fiat Industrial (Milan: FI.MI), including CaseIH, New Holland Agriculture, Case Construction, New Holland Construction, Kobelco and CNH Capital. Additional information about Titan Machinery Inc. can be found at www.titanmachinery.com.
To view recent article please visit http://crweselect.com/30850/stock-alerts/verifone-systems-international-expansion-with-isracard-ltd-pay-mrk/
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crweselect.com/disclaimer).